Hexadecylphosphocholine (Miltefosine) Has Broad-Spectrum Fungicidal Activity and Is Efficacious in a Mouse Model of Cryptococcosis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.50.2.414-421.2006PMID 16436691PMCID PMC1366877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line.

  2006cited by this paper
• Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

  2005cited by this paper
• Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome.

  2005cited by this paper
• Antiprotozoal lysophospholipid analogues: a comparison of their activity against trypanosomatid parasites and tumor cells.

  2004cited by this paper
• In Vitro Antifungal Activities of Inhibitors of Phospholipases from the Fungal Pathogen Cryptococcus neoformans

  2004cited by this paper
• Miltefosine (Impavido): the first oral treatment against leishmaniasis

  2004cited by this paper
• Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment

  2004cited by this paper
• Role of Extracellular Phospholipases and Mononuclear Phagocytes in Dissemination of Cryptococcosis in a Murine Model

  2004cited by this paper
• Phospholipases as a factor of pathogenicity in microorganisms

  2003cited by this paper
• Antiprotozoal activities of phospholipid analogues.

  2003cited by this paper
• Role of PLB1 in Pulmonary Inflammation and Cryptococcal Eicosanoid Production

  2003cited by this paper
• Successful Control of Disseminated Scedosporium prolificans Infection with a Combination of Voriconazole and Terbinafine

  2003cited by this paper
• In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates

  2003cited by this paper
• Synthesis and antiproliferative activity of alkylphosphocholines.

  2003cited by this paper
• Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs.

  2002cited by this paper
• Oral miltefosine for Indian visceral leishmaniasis.

  2002cited by this paper
• Miltefosine Zentaris.

  2002cited by this paper
• Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities.

  2001cited by this paper
• Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans

  2001cited by this paper
• Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.

  2000cited by this paper
• Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans.

  2000cited by this paper
• Synthetic analogues of irlbacholine: a novel antifungal plant metabolite isolated from Irlbachia alata.

  1999cited by this paper
• Biochemical and functional characterisation of secreted phospholipase activities from Cryptococcus neoformans in their naturally occurring state.

  1999cited by this paper
• Inhibition of GPI phospholipase C from Trypanosoma brucei by fluoro-inositol dodecylphosphonates.

  1998cited by this paper
• Induction of Ceramide-mediated Apoptosis by the Anticancer Phospholipid Analog, Hexadecylphosphocholine*

  1998cited by this paper
• Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans

  1997cited by this paper
• Phospholipase activity in Cryptococcus neoformans: a new virulence factor?

  1997cited by this paper
• Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues.

  1996cited by this paper
• Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus

  1996cited by this paper
• Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans.

  1995cited by this paper
• Phospholipid analogues: side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis.

  1994cited by this paper
• Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells.

  1992cited by this paper
• Hexadecylphosphocholine: determination of serum concentrations in rats.

  1991cited by this paper
• The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation.

  1991cited by this paper
• Phospholipase A2 inhibitors: monoacyl, monoacylamino-glycero-phosphocholines.

  1989cited by this paper
• Distribution and metabolism of hexadecylphosphocholine in mice

  1987cited by this paper
• Lysophospholipase 1 in Trypanosoma brucei.

  1981cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper

• Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?

  2025cites this paper
• Nerolidol and a zwitterionic surfactant induce membrane rigidity inLeishmania amazonensisand infected macrophages.

  2025cites this paper
• Progress in antileishmanial drugs: Mechanisms, challenges, and prospects

  2025cites this paper
• Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors

  2024cites this paper
• Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses

  2024cites this paper
• Tackling multi-drug resistant fungi by efflux pump inhibitors.

  2024cites this paper
• A budding yeast-centric view of oxysterol binding protein family function.

  2024cites this paper
• Synthesis of Keratin Nanoparticles Extracted from Human Hair through Hydrolysis with Concentrated Sulfuric Acid: Characterization and Cytotoxicity

  2024cites this paper
• Antifungal activity of miltefosine against both azole-susceptible and resistant Aspergillus strains.

  2023cites this paper
• Miltefosine: A Repurposing Drug against Mucorales Pathogens

  2023cites this paper
• Recurrent copy number variations in the human fungal pathogen Candida parapsilosis

  2023cites this paper
• Miltefosine repositioning: A review of potential alternative antifungal therapy.

  2023cites this paper
• Repurposing drugs for fungal infections: advantages and limitations.

  2023cites this paper
• Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis.

  2023cites this paper
• Phospholipase B Is Critical for Cryptococcus neoformans Survival in the Central Nervous System

  2022cites this paper
• Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?

  2022cites this paper
• Paracoccidioides brasiliensis plasma membrane characterization by EPR spectroscopy and interactions with amphotericin B, miltefosine and nerolidol

  2022cites this paper
• In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant Fusarium Strains

  2022cites this paper
• Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome

  2022cites this paper
• Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

  2022cites this paper
• Mycobacterium abscessus cell wall and plasma membrane characterization by EPR spectroscopy and effects of amphotericin B, miltefosine and nerolidol.

  2022cites this paper
• An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

  2021cites this paper
• Resistance to miltefosine results from amplification of the RTA3 floppase or inactivation of flippases in Candida parapsilosis

  2021cites this paper
• Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine

  2021cites this paper
• Miltefosine Against Scedosporium and Lomentospora Species: Antifungal Activity and Its Effects on Fungal Cells

  2021cites this paper
• Recent advances and future perspectives in the pharmacological treatment of Candida auris infections

  2021cites this paper
• Screening of chemical libraries for new antifungal drugs against Aspergillus fumigatus reveals the potential mechanism of action of miltefosine

  2021cites this paper
• Comparative EPR spectroscopy analysis of amphotericin B and miltefosine interactions with Leishmania, erythrocyte and macrophage membranes.

  2021cites this paper
• Antifungal natural products.

  2021cites this paper
• Cryptococcosis: current treatment and new possibilities

  2020cites this paper
• Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of Candida krusei

  2020cites this paper
• A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents

  2020cites this paper
• Alternative treatment of fungal infections: Synergy with non‐antifungal agents

  2020cites this paper
• Synthesis, physicochemical properties and biological activities of novel alkylphosphocholines with foscarnet moiety.

  2020cites this paper
• Reviewing the Effects of Miltefosine and Suggesting It for the Treatment of Coronavirus Disease (COVID-19)

  2020cites this paper
• Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris.

  2020cites this paper
• New Targets for the Development of Antifungal Agents

  2020cites this paper
• Non-Aspergillus Fungal Infections in Transplant Patients

  2020cites this paper
• Differential impact of synthetic antitumor lipid drugs on the membrane organization of phosphatidic acid and diacylglycerol monolayers.

  2020cites this paper
• Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis

  2020cites this paper
• Nuevos antifúngicos, nuevas dianas y estrategias terapéuticas para el tratamiento de las micosis invasoras: revisión de la bibliografía (2005-2009)

  2020cites this paper
• New Approaches for Cryptococcosis Treatment

  2020cites this paper
• Interactions of miltefosine with erythrocyte membrane proteins compared to those of ionic surfactants.

  2019cites this paper
• Electrochemical synthesis of a new phosphonium betaine. Kinetic evaluation and antibacterial susceptibility

  2019cites this paper
• Flavonoid-alkylphospholipid conjugates elicit dual inhibition of cancer cell growth and lipid accumulation.

  2019cites this paper
• In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida auris to Miltefosine Alone and in Combination with Amphotericin B

  2019cites this paper
• Evidence for biofilms in onychomycosis.

  2019cites this paper
• Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome via multiple mechanisms

  2019cites this paper
• Antileishmanial and cytotoxic activities of ionic surfactants compared to those of miltefosine.

  2019cites this paper
• Micellar curcumin improves the antibacterial activity of the alkylphosphocholines erufosine and miltefosine against pathogenic Staphyloccocus aureus strains

  2019cites this paper
• Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis

  2019cites this paper
• Insights on the anticandidal activity of non-antifungal drugs.

  2019cites this paper
• Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria

  2018cites this paper
• Emerging New Targets for the Treatment of Resistant Fungal Infections.

  2018cites this paper
• Pathobiology of Lomentospora prolificans: could this species serve as a model of primary antifungal resistance?

  2018cites this paper
• Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts

  2018cites this paper
• In vitro assessment of antifungal, antibacterial, and antiprotozoal drugs against clinical isolates of Conidiobolus lamprauges.

  2018cites this paper
• Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice

  2018cites this paper
• 1 Title : In vitro activities of miltefosine and antibacterial agents from macrolide , oxazolidinone , and 1 pleuromutilin classes against Pythium insidiosum and Pythium aphanidermatum 2 3 Running title : In vitro activities of miltefosine and antibacterials 4 5

  2018cites this paper
• In Vitro Activities of Miltefosine and Antibacterial Agents from the Macrolide, Oxazolidinone, and Pleuromutilin Classes against Pythium insidiosum and Pythium aphanidermatum

  2018cites this paper
• Distinct roles of the 7-transmembrane receptor protein Rta 3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans Rta 3 in biofilm formation and phosphocholine asymmetry

  2017cites this paper
• Tackling Fungal Resistance by Biofilm Inhibitors.

  2017cites this paper
• Distinct roles of the 7‐transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans

  2017cites this paper
• The cytotoxic activity of miltefosine against Leishmania and macrophages is associated with dynamic changes in plasma membrane proteins.

  2017cites this paper
• A P4‐ATPase subunit of the Cdc50 family plays a role in iron acquisition and virulence in Cryptococcus neoformans

  2017cites this paper
• Miltefosine is fungicidal to Paracoccidioides spp. yeast cells but subinhibitory concentrations induce melanisation.

  2017cites this paper
• The antifungal pipeline: a reality check

  2017cites this paper
• Crystal structure of new carboxylate phosphabetaines and phosphonium salts conjugated with them

  2016cites this paper
• Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells.

  2016cites this paper
• Animal Models to Evaluate Anti-infective Pharmacodynamics

  2016cites this paper
• Estudo das interações da miltefosina com membranas de L. (Leishmania) amazonensis e macrófagos peritoneais

  2016cites this paper
• Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?

  2016cites this paper
• Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages.

  2016cites this paper
• Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data.

  2016cites this paper
• In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.

  2015cites this paper
• Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs.

  2015cites this paper
• Lipids and liposomes in the enhancement of health and treatment of disease

  2015cites this paper
• Combination Therapy for the Treatment of Mucormycosis: Examining the Evidence

  2015cites this paper
• In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis

  2015cites this paper
• Could miltefosine be used as a therapy for toxoplasmosis?

  2015cites this paper
• DRUG REPURPOSING: A STUDY OF THE POTENTIAL ANTITUMORGENIC ACTIVITY OF NONCHEMOTHERAPEUTIC DRUGS

  2015cites this paper
• Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis

  2015cites this paper
• Miltefosine is effective against Candida albicans and Fusarium oxysporum nail biofilms in vitro.

  2015influential citation
• Miltefosine is active against Sporothrix brasiliensis isolates with in vitro low susceptibility to amphotericin B or itraconazole.

  2015influential citation
• In vitro antifungal activity of miltefosine and levamisole: their impact on ergosterol biosynthesis and cell permeability of dimorphic fungi

  2015influential citation
• Synthesis of structural analogues of hexadecylphosphocholine and their antineoplastic, antimicrobial and amoebicidal activity.

  2015cites this paper
• In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds

  2014cites this paper
• Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects.

  2014cites this paper
• Evaluation of the effect of miltefosine on Trichomonas vaginalis

  2014cites this paper
• Disseminated Scedosporium prolificans infection in an ‘extensive metaboliser’: navigating the minefield of drug interactions and pharmacogenomics

  2014cites this paper
• In vitro inhibitory effect of miltefosine against strains of Histoplasma capsulatum var. capsulatum and Sporothrix spp.

  2014influential citation
• Cytomorphological changes and susceptibility of clinical isolates of Acanthamoeba spp. to heterocyclic alkylphosphocholines.

  2014cites this paper
• Miltefosine Increases Lipid and Protein Dynamics in Leishmania amazonensis Membranes at Concentrations Similar to Those Needed for Cytotoxicity Activity

  2014cites this paper
• Crystal structure of phosphonium carboxylate complexes. The role of the metal coordination geometry, ligand conformation and hydrogen bonding

  2014cites this paper
• Evaluation of the inhibitory effects of miltefosine on the growth of Babesia and Theileria parasites.

  2014cites this paper
• Synthesis and antifungal activities of miltefosine analogs.

  2013cites this paper
• Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease

  2013cites this paper
• Synthesis, self-aggregation and biological properties of alkylphosphocholine and alkylphosphohomocholine derivatives of cetyltrimethylammonium bromide, cetylpyridinium bromide, benzalkonium bromide (C16) and benzethonium chloride.

  2013cites this paper
• Effect of alkylphospholipids on Candida albicans biofilm formation and maturation.

  2013cites this paper
• In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.

  2013cites this paper